Vraylar

Schizophrenia, Bipolar Disorder, Bipolar Disorder + 1 more

Treatment

20 Active Studies for Vraylar

What is Vraylar

Cariprazine

The Generic name of this drug

Treatment Summary

Cariprazine is a medication used to treat schizophrenia and bipolar disorder. It works by activating dopamine receptors in the brain to reduce symptoms of these conditions. Cariprazine is different from other antipsychotic medications because it specifically targets certain dopamine receptors. It was approved by the FDA in 2015 and can also be used as an additional treatment for major depressive disorder.

Vraylar

is the brand name

image of different drug pills on a surface

Vraylar Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vraylar

Cariprazine

2015

6

Effectiveness

How Vraylar Affects Patients

Cariprazine is an antipsychotic drug that has been used to reduce symptoms of schizophrenia and bipolar I disorder in clinical trials. Studies have also found it to be effective in treating anxiety and low mood. It works by binding to dopamine receptors, though it does so in a way that causes fewer side effects (such as restlessness and tremors) than other antipsychotics. Additionally, it has an effect on serotonin receptors that helps reduce the risk of side effects even further. However, there is still a risk of side effects with cariprazine, such as akathisia, extrapyramidal disorder, restlessness

How Vraylar works in the body

Cariprazine is a drug used to treat schizophrenia and bipolar disorder. It works by targeting dopamine receptors, which are involved in reward processing and motivation. Specifically, it binds to dopamine D2 and D3 receptors, which are associated with positive and negative symptoms of schizophrenia. It also binds to other receptors in the body, which have been linked to pro-cognitive and antidepressant effects. These effects help reduce the symptoms of schizophrenia and bipolar disorder.

When to interrupt dosage

The suggested measure of Vraylar is contingent upon the diagnosed affliction, for instance Bipolar Disorder, Acute Coryza and Schizophrenia. The amount of dosage is contingent upon the procedure of delivery featured in the table beneath.

Condition

Dosage

Administration

Mental Depression

, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg

, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule

Schizophrenia

, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg

, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule

Bipolar Disorder

, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg

, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule

Bipolar Disorder

, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg

, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule

Warnings

Vraylar Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Cariprazine may interact with Pulse Frequency

There are 20 known major drug interactions with Vraylar.

Common Vraylar Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Cariprazine may increase the antipsychotic activities of Amisulpride.

Azelastine

Major

Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Cariprazine is combined with Deutetrabenazine.

Ethanol

Major

Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methylene blue

Major

Cariprazine may increase the serotonergic activities of Methylene blue.

Vraylar Toxicity & Overdose Risk

In one case, a patient accidentally took a high dose of cariprazine (48 mg/day) and experienced dizziness and drowsiness. They fully recovered the same day. There is no specific antidote for overdose, so medical supervision and monitoring is recommended. It is also possible that multiple drugs were involved in the overdose.

image of a doctor in a lab doing drug, clinical research

Vraylar Novel Uses: Which Conditions Have a Clinical Trial Featuring Vraylar?

171 active trials are at present assessing the capability of Vraylar to manage Bipolar Disorder, Bipolar Disorder Type I and Schizophrenia.

Condition

Clinical Trials

Trial Phases

Mental Depression

2 Actively Recruiting

Phase 2, Not Applicable

Bipolar Disorder

0 Actively Recruiting

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Bipolar Disorder

0 Actively Recruiting

Vraylar Reviews: What are patients saying about Vraylar?

5

Patient Review

7/22/2022

Vraylar for Bipolar Depression

This medicine has been an absolute game-changer for me. If you're struggling with bipolar depression, I cannot recommend this highly enough. Finally, I feel free from negative thoughts and am able to lead a happy life.

5

Patient Review

7/3/2022

Vraylar for Bipolar Depression

This treatment was amazing and it really gave me my life back. I would encourage anyone struggling to not give up hope because there are options out there that can help you.

5

Patient Review

9/10/2022

Vraylar for Bipolar Depression

Vrylar has the strange side effect of making me a morning person. I go to bed just fine, but then I wake up feeling great and full of energy between 5 and 7am. This is even with taking Seroquel at night. I would rate this medication 10 out of 10.

5

Patient Review

10/26/2022

Vraylar for Bipolar Depression

I had wonderful results from this medication, however the cost is quite high. I was only able to try it because my nurse practitioner gave me some samples, but now that I need to buy it myself it's quite out of reach. If anyone has any suggestions for dealing with the cost, please let me know.

5

Patient Review

7/25/2022

Vraylar for Schizophrenia

Vraylar has been an absolute godsend. It's drastically decreased the severity and frequency of my hallucinations, both visual and auditory. Additionally, it's helped to lessen delusions and other symptoms so that I can live a relatively normal life again.

3.7

Patient Review

7/24/2022

Vraylar for Bipolar Depression

I've tried a lot of different medications, and Vraylar is by far the best one for my depression. However, I have experienced some intense side effects like nausea and headaches. Hoping that these go away with time!

3.7

Patient Review

7/25/2022

Vraylar for Bipolar Depression

This medication really helped to improve my mood. I felt less anxious and more even-keeled. Everything seemed brighter and easier to handle.

3.3

Patient Review

8/17/2021

Vraylar for Bipolar Depression

I've been taking this for a few weeks now. It's not as effective at controlling my symptoms as Olanzapine was, but the weight gain and lethargy from Olanzapine were too much. I don't sleep well and Vraylar isn't much help for that. It took a few days for the drug to take effect but when it did it works well enough. Good thing is insurance covered the cost otherwise I would not have been able to afford.

3.3

Patient Review

8/14/2022

Vraylar for Bipolar I Disorder with Most Recent Episode Mixed

At first, this treatment was working well for me. But then my anxiety started to get worse and now I'm feeling really nervous all the time.

3

Patient Review

4/4/2022

Vraylar for Bipolar I Disorder with Most Recent Episode Mixed

I gained 10 lbs while on this medication, and I was always hungry. Additionally, I experienced erectile dysfunction and low interest in sex. However, I think it did help with my delusions when I first started taking it. But the side effects were too much for me to handle.

3

Patient Review

11/3/2022

Vraylar for Bipolar Depression

After six weeks of taking Vraylar, I'm done. The constant flu-like symptoms were really getting me down--I was constantly tired and had no appetite. Abilify worked better for me.

2.3

Patient Review

9/10/2022

Vraylar for Bipolar I Disorder with Most Recent Episode Mixed

At first, I thought this medicine was amazing. But then I started putting on a lot of weight very quickly, developed diabetes, and started to feel very apathetic from low dopamine levels. If you can, get off this medication as soon as possible.

1

Patient Review

9/1/2022

Vraylar for Bipolar I Disorder with Most Recent Episode Mixed

Vraylar caused me so much anxiety and panic that it was honestly terrible. I had to stop taking the medicine because the feeling were just too intense and unbearable. It's a shame, too, because I know it works for some people.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vraylar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What symptoms does Vraylar treat?

"The goal of this medication is to improve overall depressive and manic symptoms, as well as to treat mixed episodes— when an individual experiences symptoms of both depression and mania at the same time."

Answered by AI

What are the main side effects of Vraylar?

"The following are extrapyramidal symptoms: muscle spasms, muscle rigidity, tremor, and jerking movements. Agitation, indigestion, nausea, vomiting, sleepiness, and restlessness are also common. Weight gain is a possibility."

Answered by AI

What conditions does Vraylar treat?

"Vraylar is a drug that is approved to treat mixed or manic episodes of bipolar I disorder. The drug is also approved to treat schizophrenia, as well as bipolar depression in bipolar I disorder."

Answered by AI

Is Vraylar a mood stabilizer or antipsychotic?

"The medication Vraylar can be used as an antipsychotic or an antidepressant depending on the diagnosis. If you are prescribed Vraylar, your doctor will closely monitor you for any suicidal thoughts or behaviors."

Answered by AI

What is the drug Vraylar used for?

"Cariprazine is a medication that affects the brain in order to treat schizophrenia. It is also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Cariprazine rebalances dopamine and serotonin in order to improve thinking, mood, and behavior."

Answered by AI

How does Vraylar make u feel?

"The most common side effects of VRAYLAR include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness, sleepiness, nausea, vomiting, and indigestion."

Answered by AI

Clinical Trials for Vraylar

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN

The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.

Waitlist Available
Has No Placebo

Vanderbilt Psychiatric Hospital

Heather Ward, MD

Have you considered Vraylar clinical trials?

We made a collection of clinical trials featuring Vraylar, we think they might fit your search criteria.
Go to Trials

Have you considered Vraylar clinical trials?

We made a collection of clinical trials featuring Vraylar, we think they might fit your search criteria.
Go to Trials
Image of Case Western Reserve University in Cleveland, United States.

Psychosocial Rehabilitation for Schizophrenia

18 - 50
All Sexes
Cleveland, OH

The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Model-a structured, supportive community for individuals with mental illness-has unique benefits compared to standard outpatient mental health services. If participants decide to join, they will be asked to complete a total of six study visits with the research team over the course of your participation. Three of these study visits are at the beginning (baseline) and the remaining three are six months later. Two of the three visits will includes interviews, questionnaires, and thinking and memory tasks (cognitive testing) and one session will be an MRI brain scan, which is a safe and non-invasive imaging procedure. The total time required for each visit will be approximately 90 minutes to two hours. Participants may take breaks as needed.

Waitlist Available
Has No Placebo

Case Western Reserve University

Jessica A Wojtalik, PhD

Have you considered Vraylar clinical trials?

We made a collection of clinical trials featuring Vraylar, we think they might fit your search criteria.
Go to Trials